Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. reports news about its life sciences automation business for microbial quality-control testing in healthcare manufacturing. The company develops and sells the Growth Direct platform, proprietary consumables, LIMS connectivity, software and services used to automate microbial analysis for pharmaceuticals, medical devices and personal care products.
Recurring updates include financial results and guidance, Growth Direct system placements and validations, customer orders from global biopharma and CDMO manufacturers, and company participation in healthcare investor conferences. News also covers equity compensation actions and Nasdaq-related employment inducement grants tied to its public-company governance.
Rapid Micro Biosystems (NASDAQ: RPID) reported strong Q2 2024 results, with record revenue of $6.6 million, up 32% year-over-year. The company placed its 150th Growth Direct® system and first Growth Direct Rapid Sterility system with top global pharma customers. Gross margin improved by 35 percentage points compared to Q2 2023. RPID announced an operational efficiency program expected to achieve positive cash flow without additional financing. The company reaffirmed its 2024 revenue guidance of at least $27.0 million, representing 20%+ growth. Q2 highlights include:
- Product revenue up 43.2% to $4.5 million
- Service revenue up 13.5% to $2.1 million
- Recurring revenue up 7.0% to $3.8 million
- Net loss reduced to $12.6 million ($0.29 per share)
- Cash position of $70 million with no debt
Rapid Micro Biosystems (Nasdaq: RPID), a life sciences technology company specializing in automation solutions for efficient healthcare product manufacturing, has announced its plans to release second quarter 2024 financial results before the market opens on Friday, August 2, 2024. Following the release, the company's management team will host a webcast conference call at 8:30 a.m. ET on the same day.
Investors and interested parties can access the live webcast through the company's website. The webcast will remain available for replay for one year after the event. This announcement provides an opportunity for stakeholders to gain insights into Rapid Micro Biosystems' financial performance and future outlook.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) reports a 11% growth in total revenue for the first quarter of 2024, reaching $5.6 million. The company reaffirms its full year 2024 total revenue guidance of at least $27.0 million, with growth of at least 20% compared to 2023. The first quarter saw an increase in recurring revenue by 15% to $3.7 million, including record consumable revenue. The company placed three new Growth Direct systems and completed the validation of three customer systems. Although the total cost of revenue increased by 5% to $7.1 million, the company managed to reduce its net loss and improve gross margins.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.